HACKENSACK, N.J., Aug. 8, 2018 /PRNewswire/ -- Champions Oncology,
Inc. (Nasdaq: CSBR), engaged in the development of advanced
technology solutions and services to personalize the development
and use of oncology drugs, today announced that its new facility in
Rockville, MD has been granted
Full Accreditation by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC)
International. AAALAC commended Champions for the quality and
dedication of the staff, the superior quality of the animal
facilities, the excellent program of veterinary medical care, and
the highly knowledgeable and conscientious Institutional Animal
Care and Use Committee.
The new facility was designed and constructed in the first
half of 2017 with operations initiated in July 2017. The
purpose-built facility has state-of-the-art equipment, technology,
and infrastructure, including individually ventilated caging, and
automated water systems.
Dr. Ronnie Morris, CEO of
Champions Oncology commented: "The rapidity with which our Program
attained Full Accreditation by AAALAC highlights our dedication to
animal welfare and providing the highest quality research data to
our collaborators. We are delighted and proud to join the elite
group of AAALAC-accredited
institutions."
AAALAC International is a private, nonprofit organization that
promotes the humane treatment of animals in science through
voluntary accreditation and assessment programs. Nearly 1,000
companies, universities, hospitals, government agencies and other
research institutions in 46 countries have earned AAALAC
accreditation, demonstrating their commitment to responsible animal
care and use. These institutions volunteer to
participate in AAALAC's program, in addition to complying with the
local, state and federal laws that regulate animal research.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's TumorGraft
technology platform is a novel approach to personalizing cancer
care based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting
engraftments, or TumorGrafts, in a manner that preserves the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The Company
uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. TumorGrafts are
procured through agreements with a number of institutions in the
U.S. and overseas as well as through Champions' Personalized
Oncology Solutions business. For more information, please
visit www.championsoncology.com.
View original
content:http://www.prnewswire.com/news-releases/champions-oncology-granted-full-accreditation-by-the-aaalac-300693843.html
SOURCE Champions Oncology, Inc.